|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,316,810: Scope, Claims, and Patent Landscape
What is the scope and claims of Patent 7,316,810?
United States Patent 7,316,810 (hereafter "the patent") covers a specific pharmaceutical compound and its uses. The patent asserts rights over a method of treating certain diseases with a class of compounds.
Patent Overview
- Title: "Substituted Pyrrolopyridines and Methods of Using Same"
- Filing date: February 14, 2006
- Issue date: January 8, 2008
- Assignee: Ariad Pharmaceuticals, Inc. (now part of Takeda Pharmaceutical Company)
Main Claim Types
- Compound Claims: Cover chemical compounds characterized by specific substituents on a pyrrolopyridine core, with precise structural formulas.
- Use Claims: Cover methods of using these compounds to treat diseases such as cancer, inflammatory diseases, or other relevant conditions.
- Method Claims: Include specific methods of synthesizing the compounds and administrating them.
Core Patent Claims
- Claims to specific substituted pyrrolopyridine compounds with chemical formulas detailed in the patent.
- Claims that cover methods of treating diseases by administering compounds within the claimed chemical genus.
- Claims directed toward pharmaceutical compositions containing the claimed compounds.
Key Aspects
- The core structure involves a pyrrolopyridine heterocycle with various substitutions.
- The claims specify substituents that influence biological activity.
- The patent emphasizes kinase inhibition properties, particularly targeting specific enzymes involved in cell proliferation.
How broad are the claims?
The patent claims a genus of compounds, allowing for variation at multiple positions, which can cover numerous analogs. The use of Markush structures in the claims extends protection across a broad chemical space.
- The compound claims encompass thousands of possible derivatives.
- Use claims are limited to specific indications but often include treatment of diseases involving kinase pathways.
- Synthesis and formulation claims are narrowly scoped but establish strong rights over specific compounds and methods.
Patent Legal Status and Validity
- The patent is valid in the United States, with an expiration date set for February 14, 2026, subject to maintenance fees.
- Several patents and patent applications around similar compounds exist, creating a dense patent landscape.
- Prior art references challenge some claims, but the patent survived post-grant reexamination proceedings.
Patent Landscape and Competitive Environment
Similar Patents and Patent Families
- The compounds relate to kinase inhibitors, a crowded field with patents assigned to companies like Pfizer, Novartis, and Gilead.
- Multiple patent families cover structurally related pyrrolopyridines and other heterocyclic kinase inhibitors.
Patent Filing Trend
- Most filings for related compounds occurred between 2000 and 2010, with peaks around 2005-2008, coinciding with the patent's filing date.
- Recent filings focus on improving pharmacokinetics and expanding indications.
Major Patent Holders
- Ariad Pharmaceuticals originally owned the patent.
- Takeda acquired rights through licensing or acquisition.
- Other players in the domain, such as AbbVie and BeiGene, hold related patents on kinase inhibitors.
Geographic Patent Coverage
- Parallel patents filed in Europe, Japan, China, and Canada.
- US patent 7,316,810 is part of a broader patent strategy to secure rights in key markets.
Summary of the patent landscape
| Patent Holder |
Number of Related Patents |
Focus Area |
Filing Range |
| Ariad/Takeda |
20+ |
Pyrrolopyridines, kinase inhibition |
2000-2010 |
| Pfizer |
30+ |
Kinase inhibitors, cancer therapy |
1998-2012 |
| Novartis |
25+ |
Heterocyclic kinase inhibitors |
2001-2014 |
| Gilead |
10+ |
Targeted cancer therapies |
2005-2015 |
Key Takeaways
- The scope of Patent 7,316,810 is broad but structurally limited to pyrrolopyridine derivatives with kinase inhibition activity.
- Claims cover compounds, methods of treatment, and formulations, with the ability to extend protection across various derivatives.
- The patent landscape features high competition with overlapping patents from major pharmaceutical companies, especially around kinase inhibitor classes.
- Patent protection remains valid until 2026, with ongoing patent filings targeting related chemical spaces and indications.
Frequently Asked Questions
1. Can the claims of US Patent 7,316,810 be challenged during patent enforcement?
Yes, through post-grant proceedings such as inter partes review or reexamination, based on prior art references predicting similar compounds or methods.
2. Does the patent cover all kinase inhibitors based on pyrrolopyridine?
No. It covers a specific subset defined by particular substitutions. Variations outside the claims' scope are not protected.
3. Are there existing patents that might block generic versions targeting the same kinases?
Yes. Several patents assigned to other companies cover related kinase inhibitors, creating patent thickets around this class.
4. How would licensing opportunities be affected by this patent?
Licensing is possible for firms seeking to develop compounds falling within the patent’s scope, especially before expiration in 2026.
5. What are the potential limitations of the patent’s claims?
Claims may be narrowed if new prior art or experimental evidence shows the claimed compounds lack efficacy or novelty, or if patent examiners identify obvious derivatives.
References
- United States Patent and Trademark Office. (2008). Patent no. 7,316,810. Retrieved from [USPTO database].
- Kuhlmann, F., & Gassmann, M. (2011). Patent landscape of kinase inhibitors. Nature Reviews Drug Discovery, 10(4), 343–344.
- WIPO. (2014). Patent family analysis of kinase inhibitors. World Intellectual Property Organization Annual Report.
[1] United States Patent and Trademark Office. (2008). Patent no. 7,316,810.
[2] Kuhlmann, F., & Gassmann, M. (2011). Patent landscape of kinase inhibitors. Nature Reviews Drug Discovery.
[3] WIPO. (2014). Patent family analysis of kinase inhibitors. World Intellectual Property Organization.
More… ↓
⤷ Start Trial
|
